477259-07-7

Usage

Uses

Used in Pharmaceutical Industry:
(2S)-2-amino-3-(4-iodophenyl)-1-propanol is used as a potential pharmaceutical agent due to its unique molecular structure and the presence of the 4-iodophenyl group, which may contribute to its therapeutic effects and properties.
Used in Organic Synthesis:
As a building block, (2S)-2-amino-3-(4-iodophenyl)-1-propanol is used in the synthesis of other organic molecules, leveraging its structural features to create novel compounds with potential applications in various fields.
Used in Asymmetric Synthesis:
(2S)-2-amino-3-(4-iodophenyl)-1-propanol is utilized as a chiral compound in asymmetric synthesis, allowing for the creation of enantiomerically pure products, which are essential in the development of single-enantiomer drugs.
Used in Analytical Chemistry:
In the field of analytical chemistry, (2S)-2-amino-3-(4-iodophenyl)-1-propanol serves as a chiral resolving agent, helping to separate enantiomers and analyze their properties, which is crucial for understanding the behavior and effects of chiral compounds in various chemical and biological systems.

Upstream product

• 1991-81-7 4-iodo-L-phenylalanine 

Relevant academic research and scientific papers

Discovery of a novel series of biphenyl benzoic acid derivatives as highly potent and selective human β3 adrenergic receptor agonists with good oral bioavailability. Part II

The left-hand side (LHS) and central part of our first generation biphenyl (FGB) series was modified to improve in vitro and in vivo β3-AR potency without loss of oral bioavailability. First, in this study, we focused our efforts on replacement of the 3-chlorophenyl moiety in the LHS of FGB analogues with 3-pyridyl ring analogues to adjust the lipophilicity. Second, we investigated the replacement of the central part of this series and discovered that introduction of a methyl group into the α-position of the phenethylamine moiety greatly enhanced potency keeping good oral availability. Finally, the replacement of the two carbon linker of the central part with an ethoxy-based linker provided improved potency and PK profiles. As a result of these studies, several analogues (i.e., 9h, 9k, 91, 10g, 10m, 10p, 10r, 11b, and 11l) were identified that displayed an excellent balance of very higher human β3-AR potency compared to the FGB compounds, high selectivity, and good pharmacokinetic profiles. Furthermore, these several compounds showed high in vivo efficacy in an overactive bladder (OAB) model. These findings suggest that our selected second generation biphenyl (SGB) series compounds may be attractive new successful therapeutic candidates for the treatment of OAB.